Clinical utility
study results

Envisia classifier provides UIP answers with high correlation to expert ILD histopathology results

The CATALYST study evaluated the clinical utility of Envisia classifier as an aid in the diagnosis of IPF compared to histopathology.


Two separate multidisciplinary teams (MDTs) reviewed randomized cases with clinical information, radiology images, and either histopathology images of Envisia classifier results.


Each MDT determined an IPF or non-IPF diagnosis for each patient. Study results demonstrate 86% agreement between categorical IPF diagnoses using Envisia classifier result compared to diagnoses using histopathology.1

The impact of the Envisia Genomic Classifier in the diagnosis and management of patients with idiopathic pulmonary fibrosis

In this prospective decision impact survey, the addition of Envisia Genomic Classifier improved IPF diagnostic confidence and appropriate treatment.2

Hear from peers

Discover what key opinion leaders are saying about Envisia in case studies, testimonials or on-demand presentations.


1.  Richeldi L, et al. ATS Journals. Jul 2020.
2. Lasky et al. Annals ATS Dec 2021.